Senex Biotechnology Inc., an SC Launch Inc. Portfolio Company, announced the notice of allowance for composition of matter claims on SNX631-6 and its congeners, and their use in the treatment of any cancer from the European Patent Office. This means it has passed examinations and received final approval for the use of its applications. SNX631-6 is a selective inhibitor of CDK8 and CDK19, which are pleiotropic regulators of transcriptional reprogramming, a process required for adaptive drug resistance and metastasis in cancer. Senex was granted US 11,572,369, a patent with the similar claims in 2023. Read more.
|